1. The goals of the work reported here were to further characterize benzodi
azepine/GABA(A) (BDZR) receptor heterogeneity in the cerebellum and to meas
ure the affinities and selectivities of structurally diverse benzodiazepine
s at each site identified.
2. Five chemical families were included in these studies. These were 1,4-be
nzodiazepines (flunitrazepam), imidazobenzodiazepines (RO15-1788 and RO15-4
513 and RO16-6028), beta-carbolines (Abecarnil) and pyrazoloquinolines (CGS
8216, CGS 9895 and CGS 9896).
3. Saturation and competition binding assays were combined with powerful da
ta analysis software developed in our laboratory. Among the capabilities of
this software is the identification of multiple binding sites for a cold l
igand using a non-selective labeled ligand that binds with equal, but high,
affinity to all the binding sites
4. Saturation binding assays using either [H-3]-RO15-1788 or [H-3]-RO15-451
3 revealed only one apparent binding site, with a higher affinity for RO15-
4513 than for RO15-1788. However, using [H-3]-RO15-4513 for the competition
binding studies in the cerebellum, together with our data analysis softwar
e, led to the identification of two distinct binding sites with equal densi
ties for the diverse benzodiazepines studied.
5. In rat cerebellum one of the sites identified corresponds to GABA(A) rec
eptors exhibiting alpha(6) subunit pharmacology and the other to GABA(A) re
ceptors exhibiting as subunit pharmacology. In general, the diverse familie
s of BDZR ligands studied had much lower affinities for the alpha(6) contai
ning receptors.